Citations

Mayo Clinic

Clear

88156 citation(s) found for "NA".

Ocular and Systemic Findings in COL2A1 and COL11A1 Stickler Syndrome
MacLachlan, Aileen G , Kraker, Jessica A. , Morgan, Denise J., Schimmenti, Lisa A. , Hartnett, M. Elizabeth , Hwang, Eileen S , Schimmenti, Lisa A , Hartnett, M. Elizabeth

American Journal of Medical Genetics Part A | July 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajmg.a.70244 | PMID 42458851 Get It

ABSTRACT Stickler syndrome is most commonly caused by variants in COL2A1 and COL11A1 genes. The purpose of this study was to describe genetic variants and phenotypes in COL2A1 and COL11A1 Stickler syndrome. We performed a retrospective genotype–phenotype evaluation of COL2A1 and COL11A1 Stickler syndrome subjects. Thirty‐two subjects with COL2A1 and 13 subjects with COL11A1 Stickler syndrome were last seen in clinic at a mean age of 17.2 ± 13.1 and 12.6 ± 3.8 years, respectively ( p = 0.08). We found that 50% of COL2A1 subjects had lattice degeneration, whereas 8% of the COL11A1 subjects had lattice degeneration ( p = 0.015). The most common type of variant for COL2A1 Stickler syndrome was a premature termination codon (12 out of 18 families, 67%); and the most common types of variants for COL11A1 Stickler syndrome were glycine missense variants (4 out of 10 families, 40%) and splice site variants (4 out of 10 families, 40%). There was a higher rate of lattice degeneration in COL2A1 patients compared with COL11A1 patients, a finding that could be influenced by a trend towards older age at last follow‐up in the COL2A1 group.
Interleukin-33 at the intersection of inflammation and repair
Martinez-Moreno, Fernanda, Jerschow, Elina , Ortega, V, Kita, H , Kita, Hirohito , Chiarella, Sergio E.

Frontiers in Allergy | July 16, 2026 | Volume: 7 | Issue: No issue available | Pages: No page available

10.3389/falgy.2026.1894127 | PMID 42534767 Get It

Interleukin 33 (IL-33) is a cytokine of the IL-1 family that acts as an alarmin in both innate and adaptive immunity. IL-33 is constitutively nuclear in epithelial and endothelial cells, where its activity is limited by nuclear retention. Release of IL-33 in response to cellular stress or injury can mediate type 2 immune responses or tissue repair, depending on the local tissue environment. IL-33 activity is regulated at multiple levels, including nuclear retention, oxidation, proteolytic processing, and metabolic regulation. Following its release, oxidation rapidly suppresses IL-33 activity, while mast cell and neutrophil proteases can generate smaller active fragments that target cells expressing the IL-33 ST2 receptor. Simultaneously, tissue metabolic status influences cellular responsiveness through the mTORC1 and AMPK pathways, which link metabolic capacity to effector function. These conditions may explain why IL-33 can mediate an inflammatory response, but in other circumstances, it contributes to tissue repair. Such pleiotropic properties may also underline the variability in clinical responses to IL-33/ST2-targeted therapies across various diseases. The appreciation of IL-33 as a cytokine whose activity is conditioned by its structural, redox, and metabolic environment is critical to optimizing its therapeutic potential as a target.
Female Oncofertility in Colorectal Cancer: Reproductive Uncertainties and Potential Benefits of Immunotherapy
Miscia, Michele , Cipriani, Linda , Conci, Nicole , Violante, Tommaso , Notarangelo, Leonardo, Vicenti, Rossella , Cortese, Federica, Maletta, Manuela , Doglioli, Marisol , Cobellis, Luigi, Rottoli, Matteo, Seracchioli, Renato, Raimondo, Diego , Raimondo, Diego , Violante, Tommaso , Raffone, Antonio , Cobellis, Luigi , Rottoli, Matteo , Seracchioli, Renato

Journal of Clinical Medicine | July 16, 2026 | Volume: 15 | Issue: 14 | Pages: 5549

10.3390/jcm15145549 | PMID 42513463 Get It

Early-onset colorectal cancer is increasing, making reproductive health an increasingly relevant survivorship issue. While immune checkpoint inhibitors have altered the management of deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) colorectal cancer, their implications for reproductive-age women remain insufficiently defined. We performed a focused narrative review, structured in line with the SANRA framework, to clarify this specific clinical domain. Immunotherapy may reshape female oncofertility counseling through two distinct mechanisms: direct reproductive uncertainty, including established endocrine toxicities and hypothesized, but currently unproven, direct gonadal effects; and indirect pathway-modifying effects, such as the potential avoidance of pelvic radiotherapy or radical surgery in selected patients with locally advanced dMMR/MSI-H rectal cancer. Anatomical organ preservation should not be automatically equated with functional fertility preservation. The key clinical message is that reproductive counseling should not be restricted to historically gonadotoxic chemotherapy. Instead, early multidisciplinary guidance should explicitly distinguish CRC-specific evidence from extrapolated or theoretical concerns, integrate fertility preservation strategies when clinically feasible, and address pelvic and sexual health, contraception, washout, endocrine follow-up, and future pregnancy planning. Until prospective CRC-specific reproductive data become available, immunotherapy should not be presented as either reproductively neutral or fertility-preserving.
Fluorescence In Situ Hybridization Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Testing Results From the College of American Pathologists/American College of Medical Genetics Cytogenetics Committee
Peterson, Jess F., Tang, Guilin, Mixon, Christopher, Zepeda-Mendoza, Cinthya J., Sukov, William R., Zou, Ying S., Nusapan, Rangsinee, Tan, Julian, Dvorak, James, Velagaleti, Gopalrao V., Fang, Min, Levy, Brynn, Miron, Patricia M., Cao, Yang, Astbury, Caroline, Gardner, Juli-Anne, Peterson, Jess F. , Tang, Guilin , Mixon, Christopher , Zepeda‐Mendoza, Cinthya , Sukov, William R. , Zou, Ying S , Nusapan, Rangsinee , Dvorak, James, Velagaleti, Gopalrao V.N. , Fang, Min , Miron, Patricia Minehart , Astbury, Caroline , Gardner, Juli-Anne

Archives of Pathology & Laboratory Medicine | July 16, 2026 | Volume: 150 | Issue: 12 | Pages: 942-947

10.5858/arpa.2026-0083-cp | PMID 42457191 Get It

Context.— One objective of the College of American Pathologists/American College of Medical Genetics Cytogenetics Committee is to ensure the accurate detection and clinical interpretation of abnormalities observed by fluorescence in situ hybridization (FISH) analysis when evaluating hematologic neoplasms. Objective.— To report a 20-year performance summary (2005–2024) of FISH challenges focusing on hematologic neoplasms. Design.— A retrospective review was performed from 2005 through 2024 to identify FISH challenges specifically addressing hematologic neoplasms. The overall performance of participants was evaluated to identify potential recurring errors of clinical relevance. Results.— A total of 124 hematologic neoplasm FISH challenges from 2005 to 2024 were provided to participating laboratories, including 45 paper challenges (results and/or images were provided for interpretation purposes), 43 liquid challenges (bone marrow aspirate or peripheral blood), and 36 formalin-fixed, paraffin-embedded (FFPE) tissue challenges. Of the 124 challenges, 120 (97%) exceeded the required 80% consensus for grading purposes. Of the 4 failed challenges (3%), 2 (1 liquid, 1 paper) involved the interpretation of atypical FISH signal patterns; 1 (paper) involved the interpretation of FISH signal patterns correlating involvement by myeloid versus lymphoid interphase nuclei; and 1 (liquid) likely involved a specimen processing or handling error that resulted in discordant participant responses. All 36 FFPE tissue challenges exceeded the 80% consensus for grading purposes. Conclusions.— This 20-year retrospective review demonstrates that clinical cytogenomic laboratories have been and continue to be highly proficient in the detection and interpretation of FISH abnormalities associated with hematologic neoplasms.
Psychometric Evaluation of the PRO-CTCAE Average Composite Score: Reliability, Responsiveness, Known-Groups Validity, and Sensitivity to Group Differences
Lee, Minji K. , Langlais, Blake T., Mazza, Gina L. , Thanarajasingam, Gita, Deal, Allison M. , Noble, Brie N., Rogak, Lauren , Mendoza, Tito R., Mitchell, Sandra A. , Basch, Ethan, Dueck, A. C. , Mazza, Gina L , Deal, Allison , Rogak, Lauren J , Mitchell, Sandra A , Lee, Minji K , Langlais, Blake, Thanarajasingam, Gita , Noble, Brie N. , Mendoza, Tito R. , Basch, Ethan

Cancers | July 16, 2026 | Volume: 18 | Issue: 14 | Pages: 2265

10.3390/cancers18142265 | PMID 42512331 Get It

Background/Objectives: The PRO-CTCAE Average Composite Score (ACS), calculated as the mean of PRO-CTCAE composite scores, summarizes overall symptom and side effect burden. This study evaluated the test–retest reliability, responsiveness to change, known-groups validity, and sensitivity to group differences in the ACS. Methods: Analyses used the original PRO-CTCAE validation dataset, including lung (n = 174), breast (n = 222), and head and neck (n = 139) cancer cohorts, and data from the COMET-2 randomized phase III trial comparing cabozantinib (n = 53) and mitoxantrone–prednisone (n = 54) in men with previously treated prostate cancer. Test–retest reliability was assessed using intraclass correlation coefficients (ICCs) from two-way mixed-effects models for agreement. Responsiveness was evaluated by relating ACS change scores (Visit 1 minus follow-up Visit 2) to patient-reported global ratings of change (GRC; worsened, unchanged, or improved) using standardized response means (SRMs) and Jonckheere–Terpstra trend tests. Known-groups validity was examined by comparing mean ACS values between ECOG performance status groups (0–1 vs. 2–4). Sensitivity to treatment group differences was assessed using model-based area-under-the-curve (AUC) comparisons of longitudinal ACS trajectories. Results: Test–retest reliability was acceptable, with ICCs among GRC-defined stable patients of 0.80 (95% CI: 0.70–0.87) in lung cancer, 0.84 (95% CI: 0.77–0.89) in breast cancer, and 0.77 (95% CI: 0.63–0.86) in head and neck cancer; ICCs based on assessments completed one day apart ranged from 0.88 to 0.90. The ACS demonstrated responsiveness, with SRMs of 0.30/0.15/−0.37 (lung), 0.29/0.14/−0.40 (breast), and −0.01/−0.20/−0.56 (head/neck) for improved/no-change/worsened groups, respectively, and significant monotonic trends across GRC categories (all p < 0.01). Known-groups validity was supported by conceptually expected differences in ACS values across distinct levels of self-reported patient-reported physical functioning and ECOG performance status categories. Mean ACS values were lower among patients with good versus limited physical functioning (0.71 vs. 1.23 in lung cancer, 0.52 vs. 1.19 in breast cancer, and 0.69 vs. 1.29 in head and neck cancer) and among patients with ECOG PS 0–1 versus 2–4 (0.93 vs. 1.31, 0.74 vs. 1.22, and 0.90 vs. 1.06, respectively). In COMET-2, higher symptom burden was detected in the cabozantinib arm compared with the mitoxantrone–prednisone arm (AUC difference = 1.5, 95% CI: 0.2–2.8, p = 0.02). Conclusions: The ACS demonstrated acceptable test–retest reliability, responsiveness, and known-groups validity across multiple cancer populations. These findings support its use as a complementary summary measure of overall symptomatic adverse event burden alongside individual symptom-level analyses.
Outcomes of Underwater Endoscopic Mucosal Resection for Giant Colorectal Polyps: A Multicenter Study
Karna, Rahul , Wilson, Natalie , Seid, Amir S, Larsen, Kaylee, Enke, Thomas , Hassam, Ali, Kumar, Anand R, Shah, Shawn L, Zhao, Joy, Choi, Alyssa Y, Issa, Danny, Saeed, Ahmed, Phan, Jennifer, Mosko, Jeffrey D, Dang, Frances, Westanmo, Anders, Reinink, Andrew, Samarasena, Jason B, Shaukat, Aasma, Mosko, Jeffrey D. , Bilal, Mohammad , Karna, Rahul , Larsen, Kaylee, Enke, Thomas , Choi, Alyssa Y. , Issa, Danny , Saeed, Ahmed, Phan, Jennifer, Dang, Frances , Westanmo, Anders , Reinink, Andrew R. , Samarasena, Jason , Shaukat, Aasma , Bilal, Mohammad , Wilson, Natalie

Endoscopy International Open | July 15, 2026 | Volume: 14 | Issue: CP | Pages: No page available

10.1055/a-2910-5182 | PMID 42592233 Get It

Abstract Introduction Underwater endoscopic mucosal resection (uEMR) technique has gained popularity for removal of large non-pedunculated colorectal polyps (LNPCPs) due to high en-bloc resection rates and lower recurrence rates. However, there is no information regarding outcomes of uEMR for giant colorectal polyps. Therefore, we aimed to evaluate the outcomes of uEMR for giant colorectal polyps across multiple centers in North America. Methods We conducted a multicenter retrospective study of adults with giant colorectal polyps undergoing uEMR between January 2019 and November 2025. Giant colorectal polyps were defined as LNPCPs ≥40 mm. Primary outcomes were technical success and rate of recurrent adenoma. Secondary outcomes were severe adverse events (SAEs) and predictors of technical success, recurrence, and SAEs. Results A total of 137 polyps, with mean polyp size 47.6 mm were included. Majority of the lesions were located in right colon (61%, n = 83) with the most common histopathology being high-grade dysplasia (HGD) (31.4%, n = 43). Technical success was achieved in 90.5% (n = 124) with en-bloc resection rate of 11.7% (n = 16). Polyp fibrosis (OR: 0.08) and HGD (OR: 0.15) were independent predictors of inability to achieve technical success. Of 92 (67.1%) patients with follow-up, recurrent polyp was present in 8.7% (n = 8). SAEs were noted in 9.5%, consisting of delayed bleeding (9.5%, n = 13), while no delayed perforation or post polypectomy syndrome was noted. Discussion Our study demonstrates that uEMR is technically feasible for the removal of giant colorectal polyps with an acceptable safety profile and recurrence rate.
Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection
Cisneros, Luis , Toruner, Merih Deniz , Siddiqui, Zafar , Maraone, Andrea V. , Lin, Miranda , Xiao, Alexander , Thiels, Cornelius A. , Truty, Mark J. , George, Ben , Jazieh, Khalid , Scheel, Robert , Hartley, Christopher , Elhalaby, Rofyda , Dizona, Paul , Fernández-Zapico, Martín E. , Carr, Ryan M. , Cisneros, Luis H , Toruner, Merih D , Xiao, Alexander H , Thiels, Cornelius A , Scheel, Robb , McWilliams, Robert R , Maley, Carlo C. , Hartley, Christopher P , Elhalaby, Rofyda Essam , Dizona, Paul , Shi, Qian , Fernandez-Zapico, Martin E , Carr, Ryan M , Truty, Mark J , Garzaro, Andrea V. Maraone , Lin, Miranda , George, Ben , McWilliams, Robert R. , Shi, Qian

Clinical Cancer Research | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF16

10.1158/1078-0432.ccr-25-4968 | PMID 42456051 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) frequently recurs after neoadjuvant therapy (NT) and curative-intent resection. Although major pathologic response predicts favorable outcomes, most patients achieve only minor response with a heterogeneous recurrence risk. We asked whether the spatial organization of residual PDAC encodes clinically relevant biology beyond residual tumor burden. Experimental Design: In a retrospective cohort of 203 patients with resected PDAC treated with NT and restricted to minor pathologic response, routine hematoxylin and eosin (H&E) whole-slide images were segmented into cancer and stroma using an artificial intelligence–enabled pipeline. Spatial composition (patch density, edge density) and configuration (compactness/complexity, intermixing) were quantified and tested for associations with disease-free survival (DFS) using multivariable models adjusted for standard clinicopathologic factors. Results: Shorter DFS was associated with a fragmented, interface-rich tumor–stroma ecology featuring higher edge density and diversity and reduced homotypic aggregation, independent of clinicopathologic variables. Two spatial risk models were independently prognostic: (i) cancer mean shape index plus stromal shape index variability [adjusted hazard ratio (HR), 1.71; P = 0.003] and (ii) mean stromal patch area plus edge density (adjusted HR, 2.19; P = 0.002). Both models stratified outcomes in which pathologic response grading and residual cancer area did not. High-risk configurations were further associated with reduced intratumoral tumor-infiltrating lymphocyte (TIL) density and infiltration ratio, with relative TIL accumulation at the cancer periphery and within the stroma, consistent with an immune-excluded phenotype. Conclusions: Residual cancer–stroma topology quantified from standard H&E slides yields independent prognostic signals after NT in PDAC, provides a cellular immune correlate for spatial risk, and motivates prospective validation and spatially informed adjuvant strategies.
PRANA: A Deep Learning Method for Adapting Polygenic Risk Scores to Diverse Ethnic Groups
Levi, Hagai, Wang, Qin, Bolla, Manjeet K. , Dennis, Joe, Andrulis, Irene L., Antonenkova, Natalia, Au, Chun Hang, Freeman, Laura E. Beane, Bermisheva, Marina, Bodelon, Clara, Bojesen, Stig E., Brenner, Hermann, Brock, Ian W., Brüning, Thomas, Byers, Helen, Camp, Nicola J., Castelao, Jose E., Choi, Ji-Yeob, Chung, Wendy K., Collaborators, NBCS, Colonna, Sarah, Couch, Fergus J., Daly, Mary B., Devilee, Peter, Dörk, Thilo, Eliassen, A. Heather, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Faw, Kierstin, García-Closas, Montserrat, Haiman, Christopher A., Hamann, Ute, Hartman, Mikael, Hooning, Maartje J., Hoppe, Reiner , Howell, Sacha J., Investigators, ABCTB, Investigators, SGBCC, Ito, Hidemi, Iwasaki, Motoki, Jakubowska, Anna, Jernström, Helena, Joseph, Vijai, Kaaks, Rudolf, Kang, Daehee, Khusnutdinova, Elza K., Kiprijanovska, Sanja , Koutros, Stella, Kristensen, Vessela N., Kurian, Allison W., Kwong, Ava, Lambrechts, Diether, Larson, Nicole L. , Marchand, Loic Le, Li, Shuai, Li, Jingmei, Lophatananon, Artitaya, Mannermaa, Arto, Matsuo, Keitaro, Maxwell, Whitney, Muir, Kenneth, Nevelsteen, Ines, Obi, Nadia, O’Brien, Katie M., Ofit, Kenneth, Ottewell, Penelope D., Patel, Alpa V., Plaseska-Karanfilska, Dijana, Prajzendanc, Karolina , Ramachandran, Dhanya, Rashid, Muhammad U., Saloustros, Emmanouil, Sandler, Dale P., Schöttker, Ben, Simard, Jacques, Southey, Melissa C., Stone, Jennifer, Teras, Lauren R., Truong, Thérèse, Weinberg, Clarice R., Yamaji, Taiki , Zheng, Wei, Easton, Douglas F., Elkon, Ran , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W. , Li, Shuai , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W , Li, Shuai , Levi, Hagai , Au, Chun , Augustinsson, Annelie , Freeman, Laura E. Beane , Behrens, Sabine , Bermisheva, Marina , Bodelón, Clara , Bogdanova, Natalia , Brenner, Hermann , Brock, Ian W., Brüning, Thomas , Byers, Helen, Camp, Nicola J. , Castelao, Jose E. , Choi, Ji-Yeob , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Czene, Kamila , Daly, Mary B., Devilee, Peter , Dörk, Thilo, Evans, D. Gareth , Fasching, Peter A., Faw, Kierstin, Gago-Domínguez, Manuela , García‐Closas, Montserrat , Haiman, Christopher A. , Hartman, Mikael , Ho, Vikki , Ho, Peh Joo , Hooning, Maartje J. , Investigators, S On Behalf Of The Chlovis Study, Iwasaki, Motoki , Jakubowska, Anna, Jernström, Helena , Joseph, Vijai, Kaaks, Rudolf , Хуснутдинова, Э. К. , Koutros, Stella , Kristensen, Vessela N., Kwong, Ava , Marchand, Loı̈c Le , Li, Jingmei, Lophatananon, Artitaya , Mannermaa, Arto , Nevelsteen, Ines , Obi, Nadia , O’Brien, Katie M. , Ottewell, Penelope Dawn , Peterlongo, Paolo , Plaseska‐Karanfilska, Dijana , Radice, Paolo , Ramachandran, Dhanya , Romero, Atocha , Saloustros, Emmanouil , Sandler, Dale P. , Schöttker, Ben , Simard, Jacques , Southey, Melissa C. , Sugier, Pierre‐Emmanuel , Taylor, Jack A. , Teras, Lauren R. , Truong, Thérèse , Weinberg, Clarice R. , Yadav, Siddhartha , Dunning, Alison M. , Mavaddat, Nasim , Easton, Douglas F. , Michailidou, Kyriaki , Shamir, Ron

No container title available | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.12.26357860 | PMID 42523604 Get It

Abstract Polygenic risk scores (PRSs), which quantify inherited susceptibility to complex traits and diseases, have emerged as valuable tools for risk stratification and precision medicine. Despite their promise, PRS developed on European cohorts often demonstrate substantially reduced predictive accuracy in non-European populations, due to differences in genetic architecture. The disproportionate representation of European ancestry cohorts in genome-wide association studies (GWAS) leads to inequitable deployment of PRS technologies across diverse populations. Here, we introduce PRANA (Polygenic Risk Adaptation via Neural-network Architecture), a deep learning framework that adapts an existing PRS developed on one population to other ancestries. Unlike methods that require large-scale GWAS in the target population, PRANA leverages pre-trained PRS models derived from European cohorts and adapts them using modestly sized cohorts from the target population. We evaluated PRANA on seven complex traits in South Asian, East Asian and Ashkenazi Jewish populations, as well as in selected smaller East Asian subpopulations where the scarcity of training data poses a particular challenge. PRANA mostly improved predictive performance of the baseline PRS models by 5%-20% in terms of effect size (β) and Nagelkerke’s R², and, in most cases, outperformed existing cross-ancestry multi-PRS approaches. These results highlight PRANA as a scalable and practical strategy to reduce disparities in genomic risk prediction and advance the equitable application of PRS in diverse populations.